BioSpace News Archive

SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) (OTCQB: SPRCY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced that it has agreed to sell 1,152,628 Units to certain institutional and accredited investors in a private placement at an offering price of $7.07 per Unit.

Invacare Corporation (NYSE: IVC) and its subsidiary, Alber USA, LLC announced the introduction of their next generation of power assist devices – the e-motion® (M25).

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, is pleased to announce it has completed recruitment of Cohort 1 for its upcoming first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema.

Twenty-one scientists from 14 universities and life science companies have formed the Consortium of Scientists for Pandemic Preparedness (CSPP) to combat current challenges in the COVID19 pandemic and create therapeutic, diagnostic and vaccine products to help protect against future outbreaks.

North Shore Medical Labs announced the operation of a drive-thru COVID-19 testing program at Roosevelt Field in Garden City, New York to support efforts to increase access to testing and help slow the spread of the virus.

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported financial results and operational updates for the fourth quarter and year ended Dec. 31, 2020.

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and participate at the Cowen 41st Annual Health Care Conference.

Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the third quarter of fiscal year 2021 on March 8,

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, announced that on February 26, 2021, the Company granted stock options and restricted stock units to eight new employees of the Company.

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today reported financial results for the three and twelve months ended December 31, 2020 and provided a corporate update.